Sysmex launches new automated blood coagulation analysers in EMEA region
Sysmex Europe has launched two new automated blood coagulation analysers, CN-3500 and CN-6500, in specific countries in the EMEA region. They are targeted at medium- and large-scale hospitals and commercial labs, as well as other facilities, the company says.
The new instruments come with a measuring unit that uses the chemiluminescence enzyme immunoassay (CLEIA) methodology and incorporate all the unique features of their earlier automated blood coagulation analysers CN-3000/CN-6000, making it possible to measure blood coagulation testing parameters including molecular markers for blood coagulation with a single device.
“As a result the CN-3500/CN-6500 blood coagulation analysers allow for flexible measurements in response to a broad range of test orders in the fields of thrombosis and haemostasis, such as molecular markers for blood coagulation measured with CLEIA. This is in addition to the blood coagulation and platelet aggregation parameters, which can also be measured by the predecessors CN-6000 and CN-3000,” a Sysmex spokesperson said.
Sysmex notes that there has been an increase in thrombotic diseases due to ageing populations and changing lifestyles – and, as such, the field of haemostasis has seen more diverse demands for early-stage diagnosis and appropriate treatment of such conditions.
While the demand for greater diversity in testing and prompt provision of test results to physicians is on the rise, haemostasis is typically performed by using multiple instruments with different measurement principles, such as immunoassay systems and platelet aggregation analysers in addition to blood coagulation analysers, to measure different parameters. This not only adds to the complexity of the testing workflow, but also requires lengthy waits before test results become available to determine the disease state and provide appropriate medical care, posing challenges in healthcare settings.
The CN-3500/CN-6500 are integrated analysers which will significantly improve productivity, reliability, operability, and serviceability.
In future, the company says, they will invest in the development of IVD reagents for haemostasis and immunochemistry using CLEIA.
- For more information, visit: sysmex-europe.com